The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on the NASDAQ Friday under the ticker IMPL. It is the… Read More
Seattle-based biotech firm Impel NeuroPharma closed its latest round of funding, bringing in $67.5 million to develop treatments for central nervous system disorders, such as migraines and Parkinson’s. This is… Read More